On the occasion of its 20th anniversary,ProBioGen AG announced to invest 20€ million and to double its workforce
VTU Technology and MINAPHARM Pharmaceuticals announced today, that they have entered into a licensing agreement to develop a therapeutic, recombinant Human Serum Albumin (rHSA).
Under the terms of the agreement, VTU Technology grants MINAPHARM access to VTU´s Pichia pastoris protein expression technology for rHSA production.
ProBioGen AG announced today that MINAPHARM Pharmaceuticals, Cairo, has completed the acquisition of 95 % of the share capital of ProBioGen, an internationally renowned German cell line development and contract manufacturing specialist. The total purchase price of EUR 30.4 million includes earn-out payments which are conditional upon the achievement of defined milestones.
ProBioGen will continue to be a committed technology and service provider for its global biopharmaceutical clients. The company will also continue to develop proprietary technologies in the field of biopharmaceutical products.
Cyplasin Biomedical (CPBM: OTCBB and XYI1:FRA) and Minapharnn SAE (Cairo and Alexandria Stock Exchange: MIPH) jointly announced the successful negotiation and signing of a binding term sheet agreement for the sales/marketing and distribution of Cyplasin's product C-Virin for use with chronically infected Hepatitis C patients within the Middle East and MENA regions. The agreement also encompasses the eventual manufacture and marketing of Cyplasin's future vaccine product C- Vaxin once it is available. The agreement further includes a small convertible debt loan from Minapharm to Cyplasin which will be used for initial manufacturing setups.
Langenfeld and Cairo, November 16, 2009 / b3c newswire / – ARTES Biotechnology, specialized in recombinant protein production and process development from yeast expression systems, and Rhein MINAPHARM Biogenetics, a subsidiary of MINAPHARM S.A.E. (Cairo and Alexandria Stock Exchange: MIPH) jointly announced the successful production of a new target of a therapeutic protein. This is the first result of a long-term research collaboration that was signed in January 2008. Consequently, the two companies extended their collaboration in May 2009.
During his 4 day state visit to Egypt, Rwanda president Paul Kagame and a political delegation payed an attendance to Minapharm Pharmaceuticals. He was accompanied by the Egyptian Minister for Agriculture Mr. Amen Abaza.
PolyTherics Limited (“PolyTherics”), the biopharmaceuticals company dedicated to precision engineering of proteins to improve their pharmacokinetic properties, today announced the initiation of a research collaboration agreement with Minapharm Pharmaceuticals the leading Egyptian pharmaceutical company. PolyTherics will apply its proprietary drug modification technologies to a target
Minapharm organized this event in collaboration with Repro IVF Center
The Therapeutic focus of Minapharm in the field of gynecology
Latest updates in diagnosis and treatment of diverticular disease of
Stay connected, subscribe to our newsletter for news and updates.